Company to host conference call and webcast today at 8:00 a.m. EDT The European Commission (EC) approved the 2mg/kg every-4-weeks (E4W) dosing regimen for Elfabrio® ...
Management is transitioning the ARCT-032 cystic fibrosis program into a 12-week Phase II study to better capture clinical healing and efficacy signals beyond the initial 'onboarding' phase. The ...
VANCOUVER, BC / ACCESS Newswire / March 2, 2026 / Revolve Renewable Power Corp. (CSE:REVV)(OTCQB:REVVF) ("Revolve" or the "Company"), a North American owner, operator and developer of renewable energy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results